COMPANY

Renovion

HQ: Chapel Hill, NC source · renovion.com ↗ · Southeast

Location: Chapel Hill, NC · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Pre-Bronchiolitis Obliterans Syndrome Non-cystic Fibrosis Bronchiectasis ARINA-1

Timeline

Apr 10, 2023 Trial start Phase 3: Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant source ↗
Oct 3, 2022 Trial start 2: Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough source ↗

2028-02 (ESTIMATED) · Phase 3 · Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant · NCT05654922

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05654922	Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant	Phase 3	Recruiting	Apr 10, 2023	2028-02 (estimated)
NCT05495243	Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough	2	Completed	Oct 3, 2022	Feb 1, 2024 (actual)

Annual award amounts. Total $1.8M.

Sep 11, 2021 NIH award 5R44HL151144-02 FY2021: $870,601 awarded for that fiscal year; activity R44 (SBIR); PI COPELAND, DANIEL W.; recipient as written: RENOVION, INC., CHAPEL HILL, NC. Phase 2 Clinical Trial Evaluating a Novel T source ↗
Jun 29, 2020 NIH award 1R44HL151144-01A1 FY2020: $920,791 awarded for that fiscal year; activity R44 (SBIR); PI COPELAND, DANIEL W.; recipient as written: RENOVION, INC., CHAPEL HILL, NC. Phase 2 Clinical Trial Evaluating a Novel source ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-04